 |
PDBsum entry 4jps
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Transferase/transferase inhibitor
|
PDB id
|
|
|
|
4jps
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase/transferase inhibitor
|
 |
|
Title:
|
 |
Co-crystal structures of the lipid kinase pi3k alpha with pan and isoform selective inhibitors
|
|
Structure:
|
 |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform. Chain: a. Synonym: pi3-kinase subunit alpha, pi3k-alpha, pi3kalpha, ptdins-3- kinase subunit alpha, phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kda catalytic subunit alpha, ptdins-3-kinase subunit p110-alpha, p110alpha, phosphoinositide-3-kinase catalytic alpha polypeptide, serine/threonine protein kinase pik3ca. Engineered: yes.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: pik3ca. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108. Gene: grb1, pik3r1.
|
|
Resolution:
|
 |
|
2.20Å
|
R-factor:
|
0.206
|
R-free:
|
0.228
|
|
|
Authors:
|
 |
M.S.Knapp,R.A.Elling
|
|
Key ref:
|
 |
P.Furet
et al.
(2013).
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.
Bioorg Med Chem Lett,
23,
3741-3748.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
19-Mar-13
|
Release date:
|
02-Apr-14
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chain A:
E.C.2.7.1.137
- phosphatidylinositol 3-kinase.
|
|
 |
 |
 |
 |
 |

Pathway:
|
 |
1-Phosphatidyl-myo-inositol Metabolism
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + ATP = a 1,2-diacyl- sn-glycero-3-phospho-(1D-myo-inositol-3-phosphate) + ADP + H+
|
 |
 |
 |
 |
 |
1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol)
|
+
|
ATP
|
=
|
1,2-diacyl- sn-glycero-3-phospho-(1D-myo-inositol-3-phosphate)
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
Chain A:
E.C.2.7.1.153
- phosphatidylinositol-4,5-bisphosphate 3-kinase.
|
|
 |
 |
 |
 |
 |

Pathway:
|
 |
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate) + ATP = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- trisphosphate) + ADP + H+
|
 |
 |
 |
 |
 |
1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate)
|
+
|
ATP
|
=
|
1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- trisphosphate)
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
Chain A:
E.C.2.7.11.1
- non-specific serine/threonine protein kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 5:
|
 |
Chain B:
E.C.?
|
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Bioorg Med Chem Lett
23:3741-3748
(2013)
|
|
PubMed id:
|
|
|
|
|
| |
|
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.
|
|
P.Furet,
V.Guagnano,
R.A.Fairhurst,
P.Imbach-Weese,
I.Bruce,
M.Knapp,
C.Fritsch,
F.Blasco,
J.Blanz,
R.Aichholz,
J.Hamon,
D.Fabbro,
G.Caravatti.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high
interest in anticancer drug research. On the basis of a binding model
rationalizing the high selectivity and potency of a particular series of
2-aminothiazole compounds in inhibiting PI3Kα, a medicinal chemistry program
has led to the discovery of the clinical candidate NVP-BYL719.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |
|